Tailored Drug Titration Using Artificial Intelligence
| Condition | Hypertension |
|---|---|
| Phase | N/A |
| Sponsor | Optima Integrated Health |
| Status | Completed |
| Enrollment | 165 participants |
| Interventions | optima4BP |
| Start date | Feb 18, 2020 |
| Completion date | Dec 30, 2022 |
| Results posted | Jul 20, 2026 |
Summary
The purpose of the ARTERY Outcomes study is to compare optima-for-blood pressure (optima4BP), a clinical decision support system for hypertension (HTN) treatment optimization to standard of care in patients with essential HTN.
Systolic Blood Pressure [SBP] (mmHg) Measured Remotely [Time Frame: 0 - 6 Months]
| optima4BP | 17.5 ± 5 mmHg |
|---|---|
| Standard of Care (SOC) | 15.1 ± 3.5 mmHg |
| optima4BP | 7.8 ± 0.7 mmHg |
| Standard of Care (SOC) | 5.8 ± 1.1 mmHg |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes — University of Alabama at Birmingham
- Improving Hypertension Medication Adherence for Older Adults — University of Arizona
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Ar — Actelion
- LiveSMART Trial to Prevent Falls in Patients With Cirrhosis — University of Michigan
- SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode R — Medtronic Vascular
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontro — AstraZeneca